Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody|cas:1334296-12-6|西域试剂

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody,95.0%

产品编号：Bellancom-P99268| CAS NO：1334296-12-6

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99268	￥1200.00	杭州北京（现货）
Bellancom-P99268	￥3600.00	杭州北京（现货）
Bellancom-P99268	￥5800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody

产品介绍

Seribantumab (MM 121) 是一种完全人 IgG2 单克隆抗体，靶向 HER3。Seribantumab 阻断 ErbB 家族成员及其下游信号的激活。Seribantumab 在体内、外抑制乳腺癌、肺癌和卵巢癌患者源性癌症模型中神经调节蛋白 (NRG1) 融合依赖的肿瘤发生。

生物活性

Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models.

体外研究

Seribantumab (0.1 nmol/L-10 μmol/L; 96 h) 剂量依赖性地抑制两种神经调节蛋白 1 (NRG1) 重排的融合细胞系 (MDA-MB-175-VII、DOC4-NRG1 融合和 LUAD-0061AS3、SLC3A2-NRG1 融合)，抑制 MDA-MB-175-VII、LUAD-0061AS3、MCF-7 和 HBECp53 细胞的 IC₅₀ 值分别为 0.02、1.4、45.2 和 203 μmol/L。
Seribantumab (0.1, 1 and 10 μmol/L; 24-48 h) 有效抑制 NRG1 融合或 NRG1 扩增的肿瘤细胞系的生长。
Seribantumab (0-0.5 μmol/L; 96 h) 强烈抑制 NRG1-b1 刺激的 MCF-7 细胞的生长。
Seribantumab (0-10 μmol/L; 48 h) 诱导 NRG1 重排细胞的凋亡。
Seribantumab (0-10 μmol/L; 1 h) 抑制 NRG1 下游调节因子的磷酸化。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis

Cell Line:	MDA-MB-175-VII and LUAD-0061AS3 cell lines
Concentration:	0-10 μmol/L
Incubation Time:	48 hours
Result:	Dose-dependently increased caspase 3/7 activity and induced apoptosis of NRG1 fusion-positive breast and lung cancer cell lines.

Western Blot Analysis

Cell Line:	LUAD-0061AS3 and HBECp53-CD74-NRG1 cell lines
Concentration:	0, 0.001, 0.01, 0.1, 1 and 10 μmol/L
Incubation Time:	1 hour
Result:	Inhibited the phosphorylation of EGFR, HER2, HER3, HER4, AKT and STAT3 in LUAD-0061AS3 cells. Completely inhibited HER3, AKT, p70S6K and STAT3, and reduced phosphorylation of HER2, EGFR and HER4 to a lesser extent in HBECp53-CD74-NRG1 cells.

体内研究
(In Vivo)

Seribantumab (0.6-1 mg；腹腔注射，两周一次，共注射一次) 比阿法替尼更有效地减少非小细胞肺癌肿瘤生长，阻断生长调节因子的磷酸化并诱导细胞凋亡标志物的表达。
Seribantumab (1-10 mg；腹腔注射，两周一次，共注射一次) 在高级别浆液性卵巢癌 (HGSOC) 小鼠模型中，可以消除绝大多数肿瘤细胞，并且对动物健康或体重没有显著变化。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Immunocompromised mice with LUAD-0061AS3 PDX tumors implanted
Dosage:	0.6, 0.75 and 1 mg
Administration:	Intraperitoneal injection; 0.6, 0.75 and 1 mg for once
Result:	Effectively reduced tumor growth of mice and time- and dose-dependently reduced phosphorylation of HER2, HER3, AKT, and ERK1/2. Induced the expression if proapoptotic protein, BIM.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Immunocompromised mice with LUAD-0061AS3 PDX tumors implanted
Dosage:	0.6, 0.75 and 1 mg
Administration:	Intraperitoneal injection; 0.6, 0.75 and 1 mg for once
Result:	Effectively reduced tumor growth of mice and time- and dose-dependently reduced phosphorylation of HER2, HER3, AKT, and ERK1/2. Induced the expression if proapoptotic protein, BIM.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Immunocompromised mice with LUAD-0061AS3 PDX tumors implanted
Dosage:	0.6, 0.75 and 1 mg
Administration:	Intraperitoneal injection; 0.6, 0.75 and 1 mg for once
Result:	Effectively reduced tumor growth of mice and time- and dose-dependently reduced phosphorylation of HER2, HER3, AKT, and ERK1/2. Induced the expression if proapoptotic protein, BIM.